Extended Data Table 2 Infection treatment-emergent adverse events in patients receiving elranatamab

From: Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

  1. COVID-19, coronavirus disease 2019; MedDRA Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event.
  2. a3 (2.4%) patients had grade 5 septic shock.
  3. bIncludes preferred terms in COVID-19 (narrow) standardized MedDRA queries.
  4. c25/36 (69.4%) patients developed COVID-19 or COVID-19 pneumonia and 10/36 (30.6%) only had a positive SARS-CoV-2 test without developing the disease.
  5. dOpportunistic infection TEAEs includes preferred terms: adenoviral hepatitis, adenovirus infection, cytomegalovirus infection, cytomegalovirus infection reactivation, cytomegalovirus viremia, pneumonia adenoviral, pneumonia cytomegaloviral, Pneumocystis jirovecii pneumonia.
  6. ePreferred terms both reported in the same patient.
Back to article page